1[1]Bookman MA.Gemcitabine monotherapy in rocurrent ovarian cancer:from the bench to the clinic[J].Int J Gynecol Cancer,2005,15(Suppll):12-17.
2[2]Safra T,Ron I,Boaz M,et al.Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine.A tetruspective outcome comparison between platinum-sensitive and platinum-resistant patients[J].Acts Oncol,2006,45(4):463-468.
3[3]Mutch DG,Orlando M.Goss T,et al.Randomized phase Ⅲ trial of gemcitubine compared with pegylated lipesomal doxorubicin in patients with platinum-resistant ovarian cancer[J].J Clin Oncol,2007,25(19):2811-2818.
4[4]Ferrandina G,Ludovisi M,Lorusso D.et al.Phase Ⅲ trial of gemcitabine compared with pegylated lipusomal doxorabicin in progressire or recurrent ovarian cancer[J].J Clin Oncol,2008,26(6):890-896.
5[5]Fung-Kee-Fung M,Oliver T,Elit L,et al.Optimal chemotherapy treatment for womon with recurrent ovarian cancer[J].Curr Oncol,2007,14(5):195-208.
6[6]Tay SK,Ilanchadran A,Tan TY.First-line gemcitabine and carboplatin in advanced ovarian carcinoma:a phase Ⅱ study[J].BJOG,2006,113(12):1388-1392.
7[7]Pfisterer J,Plante M,Vergote I,et al.Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:an intergroup trial of the AGO-OVAR.the NCIC CTG,and the EORTC GCG[J].J Clin Oncol,2006,24(29):4699-4707.
8[8]Poveda A.Gemcitabine in patients with ovarian cancer[J].Cancer Treat Rev,2005,Suppl 4:S29-37.
9[9]Maenpaa JU,Grenman SE,Jalkanen JT,et al.Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first -line treatment of advanced ovarian cancer:A phaseⅡstudy[J].Gynecol Oncol,2006,101(1):114-119.
10[10]Bozas G,Bamias A,Koutsoukou V,et al.Biweekly gemcitabine and cisplatin in platinum-rusistant/rofractory,paclitaxel-pretreated,ovarian and peritoneal carcinoma[J].Gynecol Oncol,2007,104(3):580-585.
5Rustin GJ, Quinn M, Thigpen T, et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovariancancer)[J]. J Natl Cancer Iv.st, 2004, 96(6): 487- 488.
6Vergote I, Rustin GJ, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) gynecologic cancer intergroup [ J]. J Natl Cancer Inst, 2000, 92(18) : 1534 - 1535.
7U dd in S, Ahm ed M, H ussain AR, et al. Bortezom ibmed iated express ion of p27K ipl ttnvugh Sphase k inase protein 2 degradation in epithelial ovarian can cer[J]. Lab Invest, 2009, 89 (10): 1115- 1127.
8Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: resporrses seen following platinum and paclitaxe [ J ]. Gynecol Oncol, 1996, 63 ( 1 ) :89 - 93.
9Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: resporu-es seen following platinum and paclitaxel[J]. Gynecot Oncol, 1996, 63 (1) :89- 93.
10Markman M. Second line treatment of ovarian cancer with singleagent gemcitabine[J]. Semin Oncol, 2002, 29( 1 Suppl 1 ) :9 - 10.
